A Community of “Accelerators”

In June of 2021, the Therapeutics Parallel Analysis (TxPA) work group of the COVID-19 Evidence Accelerator paused to conduct a retrospective or “retro”. For those of you who are unfamiliar with the expression, a retro is an opportunity to review the work of a previous cycle or “sprint” in Agile terminology. A retro allows the Evidence Accelerator community the opportunity to step back and see how far we have come, what went well, and where we could make improvements.

Working Toward Data Interoperability

When talking about data interoperability, researchers should understand that most data issues can be traced back to a lack of alignment.

Evidence Accelerator Model – A Critical Catalyst Towards A Learning Health System

Our national and global shared experience with COVID-19 crystallized the criticality of near real-time, real-world data (RWD) to generate insights and actionable information; and the imperative to drive towards a learning health system.

COVID-19 Evidence Accelerator workgroup to coordinate medication use definitions across Evidence Accelerator data partners

During a recent COVID-19 Evidence Accelerator (EvAcc) Therapeutics Parallel Analysis meeting¹ we saw the synergy and creativity that arises when multiple partners work on the same data challenges.